ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "B-Cell Targets"

  • Abstract Number: L07 • ACR Convergence 2022

    Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study

    Di Wu1, Jing Li1, Dong Xu1, Li Wang1, Jianmin Fang2, Dan Ross3 and Fengchun Zhang4, 1Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China, Beijing, China, 2Shanghai Tongji Hospital, Tongji University, Shanghai 200065, China School of Life Science and Technology, Tongji University, Shanghai 200092, China, Shanghai, China, 3RemeGen Co., San Diego, CA, 4Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China; Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, Beijing, China

    Background/Purpose: Telitacicept is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and cyclophilin ligand interactor…
  • Abstract Number: L16 • ACR Convergence 2022

    Innovative Anti-pneumococcal Vaccine Strategies versus Standard Vaccination Regimen in Patients with ANCA-associated Vasculitides Receiving Rituximab Therapy: A Multicenter Randomized Controlled Trial (PNEUMOVAS)

    Benjamin Terrier1, Laura Richert2, Grégory Pugnet3, Olivier Aumaitre4, Olivier Moranne5, Elisabeth Diot6, Alexandre Karras7, Fabrice Bonnet8, Claire De Moreuil9, Eric Hachulla10, Thomas Le Gallou11, Céline Lebas10, Francois Maurier12, Cédric Rafat7, Maxime Samson13, Jean-Francois Augusto14, Grégoire Couvrat-Devergne15, Cécile Janssen16, Thierry Martin17, Thomas Quemeneur18, Pierre-Louis Caron19, Cécile-Audrey Durel20, Khalil El Karoui7, Aurélie Grados21, Mathieu Puyade22, Virginie Rieu4, Yurdagul Uzunhan23, Jean-Francois Viallard8, Xavier Puéchal7, Loic Guillevin7, Noémie Huchet8, Hendy Abdoul7, Carine Bellera8, Frédéric Batteux7 and Odile Launay7, 1Cochin Hospital, Paris, France, 2EUCLID, Bordeaux, France, 3CHU, Toulouse, France, 4CHU, Clermont-Ferrand, France, 5CHU, Nimes, France, 6CHU, Tours, France, 7CHU, Paris, France, 8CHU, Bordeaux, France, 9CHU, Brest, France, 10CHU, Lille, France, 11CHU, Rennes, France, 12CH, Metz, France, 13CHU, Dijon, France, 14CHU, Angers, France, 15CH, La Roche sur Yon, France, 16CH, Annecy, France, 17CHU, Strasbourg, France, 18CH, Valenciennes, France, 19CHU, Grenoble, France, 20CHU, Lyon, France, 21CH, Niot, France, 22CHU, Poitiers, France, 23CHU, Bobigny, France

    Background/Purpose: Patients receiving glucocorticoids plus rituximab (RTX) show an increased risk of infection, especially invasive pneumococcal infections. Vaccine responses to influenza, Streptococcus pneumoniae and SARS-CoV-2…
  • Abstract Number: 0527 • ACR Convergence 2022

    Rituximab as Maintenance Therapy for ANCA-associated Vasculitides: Pooled Analysis and Long-term Outcome of MAINRITSAN Trials

    Florence Delestre1, Pierre Charles2, Loïc Guillevin3, Raphaël Porcher4 and Benjamin Terrier3, 1cochin Hospital, Paris, France, 2Institut Mutualiste Montsouris, Paris, France, 3National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 4Université Paris Cité, Hôtel-Dieu, Paris, France

    Background/Purpose: Maintenance therapy after induction of remission has been shown to reduce relapse rate and mortality in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The three MAINRITSAN…
  • Abstract Number: 1632 • ACR Convergence 2022

    Novel Autoantibodies Identify Sjögren’s Disease in Patients Lacking Serum IgG Specific for Ro/SS-A and La/SS-B

    Sherri Longobardi1, Charmaine Lopez-Davis1, Bhuwan Khatri1, Constantin Georgescu1, Christina Lawrence1, Astrid Rasmussen1, Lida Radfar2, R. Hal Scofield2, Robert C. Axtell1, Gabriel Pardo1, Jonathan Wren1, Kristi A Koelsch1, Joel Guthridge1, Judith James1, Christopher Lessard1 and A. Darise Farris1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK

    Background/Purpose: Classification of Sjögren's disease (SjD) requires either Ro/SS-A autoantibodies or minor salivary gland biopsy positive for focal lymphocytic infiltrates. Up to 40% of SjD…
  • Abstract Number: 0624 • ACR Convergence 2022

    CD20+ T Cells in the Synovial Fluid of Patients with Rheumatoid Arthritis Suggest a Role for Trogocytosis in Disease Pathogenesis and Activity

    Maria De Santis1, Natasa Isailovic2, Giacomo Maria Guidelli3, Daniela Renna4, Arianna Sonaglia3, Nicoletta Luciano3, Marta Caprioli5, Angela Ceribelli1, Francesca Motta6, Matteo Vecellio1, Enrico Brunetta3 and Carlo Selmi1, 1Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pieve Emanuele, Italy, 2IRCCS Humanitas Research Hospital, Rozzano (MI), Italy, Rozzano, Italy, 3IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano, Italy, 4IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Milano, Italy, 5IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pavia, Italy, 6Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano, Italy

    Background/Purpose: Approximately 1-2% of peripheral blood T cells express CD20, a marker of the B lineage, in both healthy individuals and patients with rheumatoid arthritis…
  • Abstract Number: 1677 • ACR Convergence 2022

    Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells

    Brian J. Mog1, Elana R. Shaw1, Michael S. Hwang1, Alexander H. Pearlman1, Sarah R. DiNapoli1, Suman Paul1, Chetan Bettegowda1, Nickolas Papadopoulos1, Sandra B. Gabelli1, Michelle Petri2, Antony Rosen1, Shibin Zhou1, Kenneth W. Kinzler1, Bert Vogelstein1 and Maximilian F. Konig1, 1The Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD

    Background/Purpose: Chimeric antigen receptor (CAR)-T cell therapies have revolutionized the treatment of cancer and can be curative. CD19-targeted CAR-T cells hold promise for the treatment…
  • Abstract Number: 0644 • ACR Convergence 2022

    Long-lived Plasma Cells in the Lupus Bone Marrow Are Imprinted by Interferon

    Jennifer Barnas1, Diana Alzamareh2, Neha Nandedkar-Kulkarni2, Jennifer Albrecht2, Nida Meednu2, Cameron Baker2, Andrew McDavid1 and Jennifer Anolik2, 1University of Rochester, Rochester, NY, 2University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Systemic lupus erythematous (SLE) is a complex autoimmune disorder with heterogeneous disease presentation and a multi-pronged pathogenesis. Although autoreactive plasma cells (PC) play a…
  • Abstract Number: 1869 • ACR Convergence 2022

    Looking for BlyS(BAFF) in Juvenile Dermatomyositis: A New Biomarker of Disease Activity

    Christopher Costin1, Gabrielle Morgan2, Amer Khojah3 and Lauren Pachman4, 1Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 2Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, 3Umm Al-Qura University, Makkah, Saudi Arabia, 4Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL

    Background/Purpose: B Cell Activating Factor (BAFF) is a cytokine that drives B Cell proliferation and maturation. B Cells remain an important factor in JDM immune…
  • Abstract Number: 0720 • ACR Convergence 2022

    Risk-Benefit Assessment of Primary Prophylaxis for Pneumocystis Pneumonia in Patents with Rheumatic Diseases Exposed to Rituximab: A Multicenter Cohort Study

    Jun Won Park1, Jeffrey Curtis2, Min Jung Kim3, You-Jung Ha4, Yun Jong Lee4 and Eun Bong Lee1, 1Seoul National University Hospital, Seoul, Republic of Korea, 2Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 3Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, Republic of Korea, 4Seoul National University Bundang Hospital, Seongnam, Republic of Korea

    Background/Purpose: Although previous studies suggested that primary prophylaxis for pneumocystis pneumonia (PJP) during rituximab treatment could be beneficial, it is uncertain whether this strategy should…
  • Abstract Number: 1872 • ACR Convergence 2022

    Outcome of Idiopathic Inflammatory Myositis Patients Who Received Rituximab: A Single Centre Retrospective Study

    Fahidah Alenzi1, Shirish Sangle2 and Sanna Giovanni2, 1Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia, 2Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

    Background/Purpose: Idiopathic inflammatory myositis (IIM) includes a spectrum of a rare autoimmune disease characterized by proximal muscle weakness, variable skin manifestation and extra muscular manifestations.…
  • Abstract Number: 0754 • ACR Convergence 2022

    Persistent but Disturbed Germinal Center Reaction Among 3rd SARS-CoV-2 Vaccination After Rituximab Exposure

    Ana-Luisa Stefanski1, Hector Rincon-Arevalo1, Eva Schrezenmeier2, Franziska Szelinski1, Jacob Ritter3, Yidan Chen1, Christian Meisel4, Hubert Schrezenmeier5, Andreia C. Lino6 and Thomas Dörner1, 1Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, 2Department of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin; DRFZ Berlin; Berlin Institute of Health Charité Universitätsmedizin Berlin, Berlin, Germany, 3Department of Rheumatology and Clinical Immunology, Berlin Institute of Health Charité Universitätsmedizin Berlin, Berlin, Germany, 4Department of Medical Immunology, Charité University Medicine and Labor Berlin-Charité Vivantes, Berlin, Germany, 5Institute of Transfusion Medicine, Ulm University, Ulm, Germany and Institute for Clinical Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg – Hessen and University Hospital Ulm, Ulm, Germany, 6Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany

    Background/Purpose: Durable vaccine-mediated immunity relies on the generation of long-lived plasma cells and memory B cells (MBCs), differentiating upon germinal center (GC) reactions. SARS-CoV-2 mRNA…
  • Abstract Number: 2037 • ACR Convergence 2022

    Childhood-onset Sjögren’s Syndrome Is Characterised by Dysregulated of B and T Memory Cell Frequencies: A Pilot Immunophenotyping Analysis of This Rare Disease Phenotype

    Lucia Martin-Gutierrez1, Hannah Peckham2, Anna Radziszewska2, Junjie Peng2, Oluwatomisin Nettey2, Elizabeth Jury3 and Coziana Ciurtin4, 1Centre for Rheumatology Research, Department of Medicine,University College London, London, 2Centre for Adolescent Rheumatology Versus Arthritis, Department of Medicine, University College London, London, 3University College London, London, United Kingdom, 4Centre for Adolescent Rheumatology Versus Arthritis, Department of Medicine, University College London, London, United Kingdom

    Background/Purpose: Sjögren's syndrome (SS) is an autoimmune rheumatic disease characterised by dryness resulting from chronic lymphocytic infiltration of the exocrine glands and extra glandular manifestations…
  • Abstract Number: 0977 • ACR Convergence 2022

    Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE)

    Jason S Knight1, Winn Walter Chatham2, Christine Henning3, Julia H N Harris4, Andre Van Maurik5, Roger A Levy6 and David Pisetsky7, 1University of Michigan, Division of Rheumatology, Ann Arbor, MI, 2University of Alabama at Birmingham, Clinical Immunology and Rheumatology, Birmingham, AL, 3GlaxoSmithKline, Global Medical Affairs, Durham, NC, 4GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, 5GlaxoSmithKline, Clinical Pharmacology and Experimental Medicine, Stevenage, United Kingdom, 6GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, 7Duke University Medical Center, Durham, NC

    Background/Purpose: Serological and cellular biomarkers are used in clinical practice to guide the management of SLE. Increased levels of anti-dsDNA and decreased levels of complement…
  • Abstract Number: 2065 • ACR Convergence 2022

    Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares

    Diane Zisa1, Jeffrey Zhang-Sun1, Paul Christos2 and Kyriakos Kirou1, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine/New York-Presbyterian, New York, NY

    Background/Purpose: B cell targeting agents (BCA), including belimumab (BEL) and rituximab (RTX), have been used with success in lupus nephritis (LN) patients, though identifying patients…
  • Abstract Number: 0978 • ACR Convergence 2022

    Belimumab After Rituximab Targets IgA2 Anti-dsDNA Antibody Production and Shifts Repopulating B-cells Towards an Anergic, Non-pathogenic Phenotype in Systemic Lupus Erythematosus

    Muhammad Shipa1, liliana ribeiro santos2, Dao X Nguyen1, Andrew Embleton-Thirsk1, Mariea parvaz1, David Isenberg1, Caroline Gordon3 and Michael Ehrenstein1, 1University College London, London, United Kingdom, 2University College London, London, 3Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom

    Background/Purpose: The results from the BEAT-lupus trial comparing belimumab vs placebo, both after rituximab in systemic lupus erythematosus (SLE) have recently been reported (1). We…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences